{"id":"dibrompropamidine","rwe":[],"tags":[{"label":"dibrompropamidine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Suppressor of tumorigenicity 14 protein","category":"target"},{"label":"ST14","category":"gene"},{"label":"F2","category":"gene"},{"label":"PLAU","category":"gene"},{"label":"D08AC01","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Anti-Infective Agents, Local","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"dibromopropamidine","offLabel":[],"synonyms":["dibrompropamidine","dibromopropamidine","dibrompropamidine hydrochloride","dibrompropamidine HCl","dibromopropamidine isethionate","dibromopropamidine isetionate","dibropropamidine isethionate","dibrompropamidine isetionate","dibrompropamidine isethionate","dibrompropamidine diisetionate"],"timeline":[],"aiSummary":"Dibromopropamidine is a small molecule with a verified synonym, and it has been studied in a clinical trial as a 0.1% solution for the treatment of Acanthamoeba Keratitis. The study compared dibromopropamidine to a 0.08% PHMB solution and a placebo.","approvals":[],"brandName":"Dibromopropamidine","ecosystem":[],"mechanism":{"target":"Suppressor of tumorigenicity 14 protein, Urokinase-type plasminogen activator, Prothrombin","targets":[{"gene":"ST14","source":"DrugCentral","target":"Suppressor of tumorigenicity 14 protein","protein":"Suppressor of tumorigenicity 14 protein"},{"gene":"F2","source":"DrugCentral","target":"Prothrombin","protein":"Prothrombin"},{"gene":"PLAU","source":"DrugCentral","target":"Urokinase-type plasminogen activator","protein":"Urokinase-type plasminogen activator"}],"modality":"Small Molecule","drugClass":"dibrompropamidine","explanation":"Imagine your body's cells have a 'brake' system to prevent them from growing out of control. The Suppressor of tumorigenicity 14 protein is like a key part of this brake system. Dibromopropamidine is designed to bind to this protein, which could help slow down or stop the growth of abnormal cells.","oneSentence":"Dibromopropamidine works by binding to the Suppressor of tumorigenicity 14 protein, potentially inhibiting its activity.","technicalDetail":"Dibromopropamidine exerts its effects through a mechanism involving the inhibition of the Suppressor of tumorigenicity 14 protein, although the precise molecular details of this interaction are not well understood."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3137","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DIBROMPROPAMIDINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DIBROMPROPAMIDINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:33:36.173322","biosimilars":[],"competitors":[{"drugName":"chlorhexidine","drugSlug":"chlorhexidine","fdaApproval":"1976-09-17","patentExpiry":"Oct 2, 2027","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"dibrompropamidine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"chlorhexidine","brandName":"chlorhexidine","genericName":"chlorhexidine","approvalYear":"1976","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03274895","phase":"PHASE3","title":"Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis","status":"COMPLETED","sponsor":"SIFI SpA","startDate":"2017-08-13","conditions":["Acanthamoeba Keratitis"],"enrollment":135,"completionDate":"2022-03-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"005171","UNII":"269M3QL74S","CHEBI":"CHEBI:135760","INN_ID":"450","RXNORM":"22862","UMLSCUI":"C0057799","ChEMBL_ID":"CHEMBL30044","KEGG_DRUG":"D07204","DRUGBANK_ID":"DB13548","PUBCHEM_CID":"11974","SNOMEDCT_US":"396021007","SECONDARY_CAS_RN":"614-87-9","MESH_SUPPLEMENTAL_RECORD_UI":"C053597"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":7,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"D08AC01","allCodes":["D08AC01","S01AX14"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}